Trials / Completed
CompletedNCT00934674
Study Comparing Two Different Tablet Formulations Of Bosutinib
A Single Dose Bioequivalence Study Comparing the Commercial Tablet Formulation to the Clinical Tablet of Bosutinib in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study is comparing 2 formulations of bosutinib in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SKI-606 (Bosutinib) | Arm 1 - Commercial Tablet manufactured by Excella Arm 2 - Clinical Tablet manufactured by Wyeth Montreal |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-07-08
- Last updated
- 2009-09-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00934674. Inclusion in this directory is not an endorsement.